GleamWall
中文EN

TVTX Travere Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1438533 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY49.4%
TTM net income YoY-37.2%
TTM EPS YoY-26.2%
Revenue 3-yr CAGR71.3%
Net income 3-yr CAGR—

Margins

Gross margin98.5%
Operating margin-20.5%
Net margin-18.7%
FCF margin—
EBITDA margin-12.4%

Returns

ROE-252.7%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets97.3%
Debt / equity0.00x
Current ratio3.00x
Interest coverage-15.05x

Cash quality & payout

Operating cash flow / net income-1.54x
Accruals ratio-44.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$224.56M$169.58M$127.20M$129.69M$164.86M$114.45M$81.73M$74.79M
Cost of revenue$2.87M$2.17M$1.95M$2.55M$1.58M$1.52M$4.68M$2.55M
Gross profit$221.70M$167.41M$125.25M$127.14M$163.27M$112.93M$77.05M$72.23M
R&D expense$70.30M$60.28M$57.09M$57.87M$51.89M$49.36M$46.89M$62.07M
SG&A expense$98.41M$96.11M$80.25M$101.69M$71.05M$62.58M$60.41M$69.50M
Operating income-$68.11M$3.95M-$36.91M-$32.43M$24.93M-$12.65M-$42.67M-$60.74M
Interest expense$2.14M$2.13M$2.30M$2.30M$2.75M$2.85M$2.86M$2.82M
Pretax income-$66.93M-$35.00M-$36.72M-$21.07M$25.71M-$12.73M-$41.19M-$60.34M
Income tax-$5.89M-$204,000-$120,000$921,000$8,000$20,000$39,000-$72,000
Net income-$52.34M-$34.80M-$37.10M$2.73M$25.71M-$12.76M-$41.23M-$60.26M
EBITDA-$62.91M$8.19M-$11.70M-$14.29M$40.72M$1.37M-$29.87M-$48.65M
EPS (basic)-0.55-0.37-0.40—0.29-0.14-0.47—
EPS (diluted)-0.55-0.37-0.40—0.28-0.14-0.47—
Weighted avg. shares (diluted)94.63M93.48M91.87M—102.62M88.95M88.36M—
Balance sheet
Cash & equivalents$123.54M$117.73M$78.36M$93.03M$110.93M$75.15M$61.90M$58.53M
Short-term investments$179.83M$175.91M$130.59M$145.38M$138.66M———
Receivables$107.53M$80.64M$87.30M$80.13M$82.98M$38.72M$34.38M$27.12M
Inventory$43.80M$40.05M$37.05M$36.16M$37.55M$37.68M$38.01M$41.86M
Current assets$633.45M$615.14M$392.68M$437.56M$371.11M$379.57M$374.17M$416.70M
PP&E, net$2.72M$3.23M$3.63M$4.02M$4.32M$4.56M$4.85M$5.34M
Goodwill————$800,000$800,000$800,000$800,000
Intangibles$164.11M$131.52M$110.04M$113.87M$109.44M$105.61M$103.82M$103.97M
Total assets$848.23M$799.36M$555.19M$605.19M$538.58M$555.31M$548.80M$594.12M
Current liabilities$210.91M$152.03M$125.44M$159.90M$135.07M$189.54M$182.46M$200.75M
Total liabilities$825.64M$774.84M$456.46M$490.36M$465.02M$522.56M$515.98M$535.05M
Shareholders' equity$22.58M$24.52M$98.73M$114.83M$73.56M$32.75M$32.82M$59.08M
Shares outstanding95.67M94.17M92.40M90.92M89.46M89.10M88.79M87.45M
Cash flow statement
Operating cash flow$109.11M$58.07M-$40.37M$60.68M$14.32M$4.98M-$42.19M-$35.72M
Capital expenditure————$140,000———
Free cash flow————$14.18M———
Investing cash flow-$119.63M-$206.29M$21.55M-$104.84M$86.59M$4.85M$41.29M-$80.31M
Financing cash flow$27.29M$187.52M$4.20M$26.68M-$65.34M$1.48M$3.72M$139.12M
Depreciation & amortization$5.20M$4.23M$25.21M$18.14M$15.79M$14.02M$12.80M$12.09M
Stock-based compensation$23.44M$21.79M$16.15M$11.46M$11.26M$10.65M$11.49M$9.21M

Free plan shows the latest 8 periods; Pro shows all 69 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.